To our knowledge, this case report is the first to report outcomes from the combined use of fam-trastuzumab-deruxtecan and osimertinib for the treatment of EGFR and HER2-mutant NSCLC after progression on osimertinib therapy. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.